Tremfya vs Omvoh for Ulcerative Colitis: Which to Choose?

Tremfya and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe ulcerative colitis, both newly approved for the indication. Omvoh gained UC approval in October 2023 based on LUCENT-1 and LUCENT-2. Tremfya gained UC approval in September 2024 based on QUASAR and ASTRO. Patients comparing these two within-class UC options often weigh induction flexibility, urgency outcomes, and maintenance dosing. This guide walks through the tremfya vs omvoh ulcerative colitis comparison.

Same Class, Two Molecules

Tremfya (guselkumab) and Omvoh (mirikizumab) both bind the p19 subunit of interleukin-23, selectively blocking IL-23 signaling while preserving IL-12. IL-23 drives Th17 inflammation central to UC pathology. The guselkumab vs mirikizumab UC distinction is a within-class decision: the structural mechanism is shared, but the molecules differ in affinity, half-life, and the clinical programs that support each.

Trial Evidence: QUASAR/ASTRO vs LUCENT

Tremfya's UC approval rests on QUASAR, which showed 23% clinical remission on guselkumab versus 8% on placebo at week 12, and ASTRO, which specifically evaluated fully subcutaneous induction and demonstrated that patients could skip IV induction entirely. Omvoh's UC approval rests on LUCENT-1 (induction) and LUCENT-2 (maintenance). LUCENT-1 showed clinical remission rates of 24.2% on Omvoh versus 13.3% on placebo at week 12, with endoscopic remission, symptomatic remission, and bowel urgency improvement also significantly better. LUCENT-2 showed 49.9% of Omvoh patients in clinical remission at week 40 versus 25.1% on placebo. The QUASAR vs LUCENT comparison is informative because QUASAR paired with ASTRO uniquely supports SC-only induction, while LUCENT captured bowel urgency as a rigorous patient-reported outcome.

Efficacy Comparison

No head-to-head trial has directly compared Tremfya with Omvoh in UC. Indirect comparisons suggest similar clinical remission rates between the two drugs. For tremfya vs omvoh UC effectiveness, current data does not establish a clear winner, and decision-making often defaults to dosing preference and insurance coverage.

Bowel Urgency Outcomes

A distinctive feature of Omvoh's data is bowel urgency improvement. LUCENT showed significant improvement in urgency numerical rating scale scores at both induction and maintenance. Tremfya's QUASAR program did capture urgency data, though Omvoh's urgency outcome package is more extensively positioned in the label. For UC patients whose primary quality-of-life concern is urgency rather than stool frequency, Omvoh's data package is distinctive in a way that may inform the choice.

Onset of Action

Both drugs produce clinically meaningful UC response by week 12. The induction endpoints are comparable. For patients in active flare who need rapid improvement, the two drugs are comparable in practice.

Administration and Dosing

Tremfya for UC offers a distinctive dual induction pathway. Patients can choose IV induction (200 mg at weeks 0, 4, and 8) or fully subcutaneous induction (400 mg at weeks 0, 4, and 8) per the QUASAR and ASTRO programs. Maintenance is 100 mg SC every 8 weeks or 200 mg SC every 4 weeks. Omvoh for UC uses IV induction at 300 mg every 4 weeks for three doses (weeks 0, 4, and 8), followed by subcutaneous maintenance at 200 mg every 4 weeks, per Lilly's Omvoh prescribing information. For UC patients who want to avoid infusion center visits entirely, Tremfya's SC-only induction option is a meaningful practical advantage. For maintenance, Tremfya's every-8-week SC cadence is less frequent than Omvoh's every-4-week SC maintenance.

Safety Profiles

Both drugs have favorable safety profiles consistent with IL-23 p19 class effects. Long-term data from each drug's other indications supports low rates of serious infection and malignancy. For tremfya vs omvoh side effects, common adverse events on both drugs include upper respiratory infections, injection site reactions, and headache. Neither drug has a black-box warning for lymphoma or other class-level serious adverse events seen with anti-TNFs. TB and hepatitis B screening is recommended before starting either drug.

Anti-TNF Experienced Patients

Both Tremfya's QUASAR and Omvoh's LUCENT-1 included biologic-experienced UC patients, with meaningful response rates in each population. For UC patients who have already failed an anti-TNF, either drug is a reasonable mechanism-switch option. Your GI will weigh prior biologic exposure pattern, current disease severity, and comorbidities when making the recommendation.

Cost and Access

Both Tremfya and Omvoh are branded biologics without biosimilar competition. Insurance coverage varies by plan, and prior authorization is typically required for both drugs in UC. Manufacturer copay assistance programs exist for commercially insured patients on both drugs.

Choosing With Your GI

For a UC patient deciding between Tremfya and Omvoh, Tremfya tends to win on induction flexibility (SC or IV via QUASAR and ASTRO) and less frequent SC maintenance. Omvoh tends to win on distinctive bowel urgency outcomes from LUCENT and a longer UC track record (approved October 2023 versus September 2024). Ask your GI which drug they have the most experience with, how response will be measured after induction, what to do if symptoms persist, and how your insurance handles each option. A log of stool frequency, urgency episodes, blood, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.